What are the differential diagnoses for a peptic ulcer?

Differential Diagnosis for Peptic Ulcer Disease

When evaluating a patient with suspected peptic ulcer disease, the primary differential diagnoses include functional dyspepsia (the most common finding at endoscopy), gastroesophageal reflux disease (GERD), gastric malignancy, Zollinger-Ellison syndrome, and other causes of upper abdominal pain.

Primary Differential Diagnoses

Functional Dyspepsia

• Most patients with dyspepsia undergoing endoscopy are found to have functional dyspepsia rather than peptic ulcer disease 1
• Peptic ulcer accounts for only approximately 10% of upper gastrointestinal symptoms in patients presenting with dyspepsia 1
• Functional dyspepsia presents with chronic or recurrent upper abdominal pain or discomfort without structural abnormalities on endoscopy 1

Gastroesophageal Reflux Disease (GERD)

• More than 50% of patients with GERD will not have evidence of esophagitis at endoscopy, making it easily confused with functional dyspepsia or peptic ulcer 1
• There is considerable symptom overlap between dyspepsia and GERD in uninvestigated patients 1
• Patients with predominant or frequent heartburn (occurring more than once weekly) or acid regurgitation should be considered to have GERD until proven otherwise 1

Gastric Malignancy

• Since some gastric ulcers are actually carcinomas, it is absolutely necessary to obtain multiple biopsies during endoscopy 2
• Differential diagnosis between ulcers and infiltrative-ulcerative gastric cancer is critical 3
• Alarm features necessitating early endoscopy include new-onset dyspepsia in patients over age 50-55 years 1, 4

Drug-Induced Ulcers

• Nonsteroidal anti-inflammatory drugs (NSAIDs) are etiologic factors in approximately 36% of people with peptic ulcer disease 5
• Antiplatelet and anticoagulant therapy are associated with significant risk of upper gastrointestinal bleeding 6
• Risk medication use is found in 80% of patients with bleeding ulcers and erosions, compared to 34% in the background population 6

Helicobacter pylori-Related Disease

• H. pylori infection affects approximately 42% of patients with peptic ulcer disease 5
• H. pylori is the main cause of peptic ulcers not associated with NSAIDs 1
• Only 34.6% of patients with bleeding ulcers test positive for H. pylori infection in recent studies 6

Rare but Important Differential Diagnoses

Zollinger-Ellison Syndrome

• Should be suspected when ulcer disease presents atypically, aggressively, or in families 4
• Diagnosis is not difficult to confirm once suspected 4
• Requires consideration in patients with intractable duodenal ulcers 2, 4

Symptomatic Gastroduodenal Ulcers

• Criteria exist for differential diagnosis between true peptic ulcer and symptomatic gastroduodenal ulcers from other causes 3
• These may occur secondary to other systemic conditions or medications 2

Key Diagnostic Approach

Risk Factor Assessment

• Accurate anamnestic evaluation should identify risk factors including cigarette smoking, stress, and NSAID therapy 2
• Review of all medications, particularly antiplatelet agents, anticoagulants, and NSAIDs 6, 5

Endoscopic Evaluation

• Endoscopy is the diagnostic means of choice and definitively diagnoses peptic ulcer disease 2, 5
• Enables easy H. pylori detection 2
• Multiple biopsies are mandatory for gastric ulcers to exclude malignancy 2

H. pylori Testing

• Testing should be performed with 13C-urea breath test or stool antigen test in patients ≤55 years without alarm features 1
• Serologic, urea breath, or stool antigen tests are appropriate options 7
• Physicians should not test unless willing to treat based on a positive result 7

Clinical Pitfalls to Avoid

• Do not assume typical peptic ulcer symptoms exclude other diagnoses—symptom overlap is substantial 1
• Never diagnose a gastric ulcer without biopsy confirmation to exclude malignancy 2
• Recognize that only 8.9% of patients with bleeding ulcers receive appropriate PPI prophylaxis despite high-risk medication use 6
• Consider that H. pylori prevalence is decreasing in North America, making NSAID-related disease increasingly common 1, 6